Details of the Drug

General Information of Drug (ID: DM9S5I1)

Drug Name
TC-210
Indication
Disease Entry ICD 11 Status REF
Cholangiocarcinoma 2C12.10 Phase 1/2 [1]
Non-small-cell lung cancer 2C25 Phase 1/2 [1]
Ovarian cancer 2C73 Phase 1/2 [1]
Peritoneal mesothelioma 2C51.2 Phase 1/2 [1]
Drug Type
TCR-T cell therapy
Cross-matching ID
TTD ID
DX6O9V
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mesothelin (MSLN) TT4RXME MSLN_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03907852) Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of TCR2 Therapeutics.